← Travere Therapeutics, Inc. (TVTX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Travere Therapeutics, Inc. (TVTX)
Pharmaceutical Preparations · market cap $5.6B · as of 2026-07-13
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-29 (est.)
Earnings
Pipeline
5
programs
Upcoming events
5
next 90d+
Dossier
Ready
cached
Travere Therapeutics (TVTX) is a ~$5.3B market-cap specialty pharma focused on rare kidney and metabolic diseases, with a pipeline centered on Focal Segmental Glomerulosclerosis (FSGS), IgA Nephropathy (IgAN), and Homocystinuria. The company carries $78.4M cash against $233.7M net debt, implying a runway of roughly 5-6 months absent new financing or revenue acceleration. Revenue has grown sharply to $491M in 2025 from $145M in 2023, suggesting at least one commercial product is scaling, though the company remains net-loss-generating.
The catalyst path
- 2026-10-29 (est.)Earningsimp 5/10
- 2027-03-12 (est.)Phase 2 · Sparsentanimp 7/10
- 2027-07-15 (est.)Phase 2 · Pegtibatinaseimp 7/10
- 2027-07-15 (est.)Phase 3 · Pegtibatinaseimp 9/10
- 2027-08-15 (est.)Phase 3 · Pegtibatinaseimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| RE-021 (Sparsentan) | Phase 2 | Focal Segmental Glomerulosclerosis |
| Irbesartan | Phase 3 | Focal Segmental Glomerulosclerosis |
| Pegtibatinase | Phase 3 | Homocystinuria |
| Sparsentan | Phase 3 | Focal Segmental Glomerulosclerosis |
| Dapagliflozin | Phase 3 | Immunoglobulin A Nephropathy |
Price & technical context
3-month
+4.5%
6-month
+98.2%
12-month
+146.4%
52-wk range
$24.22–$67.52
vs 50-day MA
-5.4%
vs 200-day MA
+31.5%
Realized vol
61.5%
Max drawdown
-43.2%
Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for TVTX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.